These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38981103)

  • 1. Comparison table: Some drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2024 Jul; 66(1706):e112-e114. PubMed ID: 38981103
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2024 Jul; 66(1706):105-112. PubMed ID: 38981102
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2020 Jul; 62(1602):105-112. PubMed ID: 32728009
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison table: some drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2020 Jul; 62(1546):e112-e114. PubMed ID: 32728010
    [No Abstract]   [Full Text] [Related]  

  • 5. Romosozumab (Evenity) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2019 Jun; 61(1573):83-86. PubMed ID: 31170119
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).
    Tan X; Wen F; Yang W; Xie JY; Ding LL; Mo YX
    Menopause; 2019 Aug; 26(8):929-939. PubMed ID: 31021904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
    Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH
    J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
    Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
    Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
    Iwamoto J; Takeda T; Sato Y
    Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
    Ayers C; Kansagara D; Lazur B; Fu R; Kwon A; Harrod C
    Ann Intern Med; 2023 Feb; 176(2):182-195. PubMed ID: 36592455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romosozumab: A Review in Postmenopausal Osteoporosis.
    Paik J; Scott LJ
    Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
    Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
    J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
    Reginster JY
    Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis.
    O'Connell MB
    J Manag Care Pharm; 2006 Jul; 12(6 Suppl A):S10-9; quiz S26-8. PubMed ID: 17269853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
    Langdahl B
    Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
    Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
    Wien Med Wochenschr; 2010 Dec; 160(21-22):586-9. PubMed ID: 21170699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.